RECRUITING

Blood Markers of Early Pancreas Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.

Official Title

A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer

Quick Facts

Study Start:2018-07-26
Study Completion:2028-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03568630

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:19 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥19
  2. * Able to provide written, informed consent
  3. * Able to attend an in-person study visit in Omaha, NE twice a year to collect blood samples
  4. * Must also meet criteria for one specific cohort. Participants who meet criteria for more than one cohort are eligible.
  1. * Personal history of pancreatic ductal adenocarcinoma (PDAC)
  2. * Currently receiving treatment for a cancer diagnosis (excluding long-term hormonal therapy)
  3. * Pre-diabetes on metformin for ≥ 3 years

Contacts and Locations

Study Contact

Suzanne M Wessling, RN, BSN
CONTACT
402-559-1577
suzanne.wessling@unmc.edu
Kelsey A Klute, MD
CONTACT
402-559-8500
kelsey.klute@unmc.edu

Principal Investigator

Kelsey A Klute, MD
PRINCIPAL_INVESTIGATOR
University of Nebraska

Study Locations (Sites)

Unversity of Nebraska Medical Center
Omaha, Nebraska, 68198
United States

Collaborators and Investigators

Sponsor: University of Nebraska

  • Kelsey A Klute, MD, PRINCIPAL_INVESTIGATOR, University of Nebraska

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-07-26
Study Completion Date2028-07

Study Record Updates

Study Start Date2018-07-26
Study Completion Date2028-07

Terms related to this study

Additional Relevant MeSH Terms

  • Diabetes Mellitus, Type 2
  • PreDiabetes
  • Pancreas Cyst
  • Chronic Pancreatitis
  • Genetic Predisposition to Disease
  • Inherited Disease